Silence Therapeutics (SLN) Revenue (2024 - 2026)

Silence Therapeutics has disclosed Revenue across 3 years of filings, most recently posting $422000.0 for Q1 2026.

• Revenue for Q1 2026 came in at $422000.0, up 197.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $815000.0 (down 97.06% YoY), and the FY2025 annual result was $559000.0, down 98.71% from the prior year.
• Revenue came in at $422000.0 for Q1 2026 at Silence Therapeutics, up from $34000.0 in the prior quarter.
• In the past five years, Revenue ranged from a high of $25.3 million in Q4 2024 to a low of $34000.0 in Q4 2025.
• The 3-year median for Revenue is $422000.0 (2026), against an average of $4.9 million.
• Across the five-year window, Revenue plunged 99.87% in 2025 and soared 197.18% in 2026, its largest moves.
• Silence Therapeutics' Revenue stood at $25.3 million in 2024, then slumped by 99.87% to $34000.0 in 2025, then surged by 1141.18% to $422000.0 in 2026.
• The last three Revenue figures came in at $422000.0 (Q1 2026), $34000.0 (Q4 2025), and $159000.0 (Q3 2025), per Business Quant data.